Key result
L-carnitine added to cardioplegic solution significantly attenuated myocardial injury and improved left ventricular ejection fraction in patients with RVHD undergoing CPB surgery.
Why the study?
Myocardial ischaemia-reperfusion injury is a major complication after CPB surgery, and the protective effect and mechanism of L-carnitine in patients with rheumatic valvular heart disease undergoing CPB needed investigation.
Does L-carnitine added to cardioplegic solution reduce myocardial ischaemia-reperfusion injury in patients with rheumatic valvular heart disease undergoing CPB surgery?
RCT
randomized
Does L-carnitine added to cardioplegic solution reduce myocardial ischaemia-reperfusion injury in patients with rheumatic valvular heart disease undergoing CPB surgery?
L-carnitine added to cardioplegia may protect against myocardial ischaemia-reperfusion injury during CPB surgery for rheumatic valvular heart disease by modulating NF-κB and Nrf2 pathways.
Supports L-carnitine addition to cardioplegia in rheumatic valvular CPB surgery; extends cardioprotection evidence during ischaemia-reperfusion.
Myocardial ischaemia-reperfusion injury (MIRI) is a main pathophysiologic change following CPB surgery. L-carnitine, a natural amino acid, is able to transport fatty acids for generating energy and has a protective effect on MIRI. We aim to investigate the protective effect of L-carnitine on MIRI in patients with rheumatic valvular heart disease (RVHD) performed CPB surgical operation and the underlying mechanism. In this study, patients were randomized to three groups. L-carnitine was added to the crystalloid cardioplegic solution for experimental group 1 (6 g/L) and experimental group 2 (12 g/L), whereas no L-carnitine was used in the control group. Our results showed that L-carnitine significantly attenuated myocardial injury after surgery in these patients. L-carnitine decreased serum markers of myocardial injury including CK-MB, cTnI, hs-cTnT and IMA. L-carnitine increased left ventricular ejection fraction (LVEF) but reduced wall motion score index (WMSI) after operation. L-carnitine also inhibited myeloperoxidase (MPO) activity and inflammatory cytokines in the myocardium of patients after unclamping the aorta. Additionally, L-carnitine increased levels of superoxide dismutase (SOD) and catalase (CAT) while decreased levels of malondialdehyde (MDA) and protein carbonyl content in the myocardium of patients after unclamping the aorta. Moreover, L-carnitine suppressed the activation of nuclear factor kappa B (NF-κB) and activated nuclear factor erythroid 2-related factor 2 (Nrf2). There was also no significant difference in these indices between two experimental groups after unclamping the aorta. Taken together, L-carnitine had a protective effect against CPB-induced MIRI in patients with RVHD, which might be related to its modulation of NF-κB and Nrf2 activities.
No takes yet. Share an insight, caveat, or question.
Li et al. (2019) conducted an RCT in rheumatic valvular heart disease (RVHD). L-carnitine vs. No L-carnitine was evaluated on Myocardial injury (assessed by serum markers CK-MB, cTnI, hs-cTnT, and IMA). L-carnitine added to cardioplegic solution significantly attenuated myocardial injury and improved left ventricular ejection fraction in patients with RVHD undergoing CPB surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: